Evidence map›Paper›PMID 31494256›Full record

ReviewProgress in retinal and eye research2020

Retinal stem cell transplantation: Balancing safety and potential.

Mandeep S Singh, Susanna S Park, Thomas A Albini, M Valeria Canto-Soler, Henry Klassen, Robert E MacLaren, Masayo Takahashi, Aaron Nagiel, Steven D Schwartz, Kapil Bharti

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in retinal and eye research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed, 2 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 228 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Neural Vision Restoration in Ophthalmology.Annals of biomedical engineering · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Optogenetic vision restoration in the face of secondary and tertiary remodeling in the rd1 mouse retina.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article

82 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

Mandeep S SinghWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. Electronic address: mandeep@jhmi.edu.
Susanna S ParkDepartment of Ophthalmology & Vision Science, University of California-Davis Eye Center, Sacramento, CA, 95817, USA.
Thomas A AlbiniBascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
M Valeria Canto-SolerCellSight Ocular Stem Cell and Regeneration Research Program, Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, 80045, USA.
Henry KlassenGavin Herbert Eye Institute and Stem Cell Research Center, Irvine, CA, 92697, USA.
Robert E MacLarenNuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford and Oxford University Eye Hospital, NHS Foundation Trust, NIHR Biomedical Research Centre, Oxford, OX3 9DU, UK.
Masayo TakahashiLaboratory for Retinal Regeneration, Center for Biosystems Dynamics Research, RIKEN, Kobe, Hyogo, 650-0047, Japan.
Aaron NagielThe Vision Center, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA, 90027, USA; USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90007, USA.
Steven D SchwartzStein Eye Institute, University of California Los Angeles Geffen School of Medicine, Los Angeles, CA, 90095, USA; Edythe and Eli Broad Stem Cell Institute, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Kapil BhartiNational Eye Institute, National Institutes of Health, Bethesda, MD, 90892, USA.
Johns Hopkins University · USNational Institutes of Health · USRIKEN Center for Biosystems Dynamics Research · JPUniversity of California, Davis · USUniversity of California, Los Angeles · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Miami · USUniversity of Oxford · GBUniversity of Southern California · US

Funding

Developing autologous iPSC-RPE based IND for AMD patientsZIAEY000542 · NEI · NATIONAL EYE INSTITUTE · PI BHARTI, KAPIL · 2014 to 2025
$24.2M
VISUAL SCIENCE RESEARCH CTR SUPPORTP30EY001319 · NEI · UNIVERSITY OF ROCHESTER · PI Susana Marcos · 1985 to 2026
$17.5M
Developing functional and authenticated RPE tissue from iPS cellsZIAEY000533 · NEI · NATIONAL EYE INSTITUTE · PI BHARTI, KAPIL · 2013 to 2025
$14.4M
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Dmitry V Ivanov · 2004 to 2026
$12.2M
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein OcclusionUG1EY026876 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PARK, SUSANNA S · 2018 to 2022
$2.6M
Mechanisms of retinal cell differentiationR01EY022631 · NEI · UNIVERSITY OF COLORADO DENVER · PI CANTO-SOLER, MARIA VALERIA · 2012 to 2016
$2.0M
Department of HealthIntramural NIH HHS ZIA EY000533Intramural NIH HHS ZIA EY000542NEI NIH HHS P30 EY001319NEI NIH HHS P30 EY014801NEI NIH HHS R01 EY022631NEI NIH HHS UG1 EY026876
6 · The paper itself

Abstract

Stem cell transplantation holds great promise as a potential treatment for currently incurable retinal degenerative diseases that cause poor vision and blindness. Recently, safety data have emerged from several Phase I/II clinical trials of retinal stem cell transplantation. These clinical trials, usually run in partnership with academic institutions, are based on sound preclinical studies and are focused on patient safety. However, reports of serious adverse events arising from cell therapy in other poorly regulated centers have now emerged in the lay and scientific press. While progress in stem cell research for blindness has been greeted with great enthusiasm by patients, scientists, doctors and industry alike, these adverse events have raised concerns about the safety of retinal stem cell transplantation and whether patients are truly protected from undue harm. The aim of this review is to summarize and appraise the safety of human retinal stem cell transplantation in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.

Indexed as

Cell- and Tissue-Based TherapyHumansInduced Pluripotent Stem CellsRetinaRetinal DegenerationRetinal Pigment EpitheliumStem Cell Transplantation

Identifiers

PMID31494256
PMCPMC7056514
OpenAlexW2971597914

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.